INS and Insulin resistance: Changes in fasting insulin (2.78 ± 1.57 and 1.73 ± 2.27 μIU/ml in the placebo and PP groups, respectively; P = 0.81) and homeostatic model assessment for insulin resistance (HOMA-IR) (0.39 ± 0.68 and 0.83 ± 1.20 in the placebo and PP groups, respectively; P = 0.93) were not significantly different when comparing two groups during the study in raw and even adjusted model.